Goldman Sachs Stick to Their Buy Rating for Health Catalyst By Investing.com – Investing.com

Goldman Sachs Stick to Their Buy Rating for Health Catalyst By Investing.com – Investing.com

Goldman Sachs (NYSE:) analyst Goldman Sachs maintained a Buy rating on Health Catalyst (NASDAQ:) on Friday, setting a price target of $60, which is approximately 12.72% above the present share price of $53.23.

expects Health Catalyst to post earnings per share (EPS) of -$1.01 for the second quarter of 2021.

The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Health Catalyst, with an average price target of $59.25.
The analysts price targets range from a high of $63 to a low of $52.